+ Watch CAH
on My Watchlist
The Company is a provider of products and services that improve the safety and productivity of healthcare.
decent company with solid fundamentals - pays a nice dividend...
Here I was with a positive call on CAH until just about ten days ago. Then came the smashing news that they failed to extend their contract with WAG, being replaced by ABC. Now they have to make sure they can renew their contract with CVS--or else they'll really get hammered--and that right there puts them in a weak bargaining position. This company is going to lose literally billions in market cap within a period of months.
Just sold my position in CAH this morning on the moderate uptick in price. This is a good company, solid fundamentals and pays a nice dividend. Sold as part of a re-balance effort. There are more attractive growth opportunities and blue chippers out there that will outperform the market.
Great P/E and P/S, 2% dividend yield. Strong company with a strong future ahead.
Baby boomers largest group and they like and want their drugs. It pays 2% divided.
Betting on an Ohio company that's also a leader in the medical industry. Cardinal should be well-positioned regardless of what happens to Washington's push for socialized medicine.
Dividend will keep this solid.
4/12 screen #2: percentile and CSspeculating with new screen, high analyst opinion
A winner from the health care reform
This is not a screaming deal but with the dividend factored in it looks like they should be priced between $42 and $50. EPS growth is around 3.5% for the past 8 years (with moderate variance), revenue growth is more consistent and around 9.5%.Their net margin is low, debt is average, return on assets is high. They compete directly with AmerisourceBergen and McKesson; all three seem to be quality companies with similar performance potential.
Recession proof niche.
Long term buy
New filibuster-proof Congress should reduce the risk of any sweeping health care changes in the near future. Their focus on growing generics would help them remain competitive regardless. Solid ROE, good work being done to increase focus on core competancies, and pharmaceuticals should continue to have recession- and inflation-resistant demand.
i have bought in at 27.90 and profited from this one.good company a benjamin graham pick. its currently at 12p/e and still a bargain.
This met a high level screen to indicate a buy and strong outperform against its peers (other tickers in its industry). My 1st version of this spreadsheet devles deep into the company's balnace sheet and recent income statements, combined with other relevant price data for the company including insider/institutional holdings, short interest, debt levels, etc. Testing capabilities of this 1st version of my automated, valuation spreadhseet matched with my personal criteria and see how it holds up.
They have made significant investments in themselves over the prior 10 years. They meant business and will weather the storm.
Current spinoff not such a bad thing. My mother has been with them 32+yrs, just had a little talk and she has decided to take a larger position in company. I believe they have been undervalued for some time and no matter what current administration does they will benefit due to "tentacles" they have had for some time. They are trading at about 50% discount to historical values, p/e and compared to others. Fundamentaly sound company that gets no respect!
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions